Abstract
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an increasingly recognized cause of ventricular tachycardia and sudden cardiac death in young people, notably young athletes. The best treatment is not clear, although options include antiarrhythmic drugs, radiofrequency ablation, and implantable defibrillators.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
